Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with vari… Read more
Avicanna Inc (AVCNF) - Total Liabilities
Latest total liabilities as of September 2025: $9.47 Million USD
Based on the latest financial reports, Avicanna Inc (AVCNF) has total liabilities worth $9.47 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Avicanna Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Avicanna Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Avicanna Inc Competitors by Total Liabilities
The table below lists competitors of Avicanna Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dongbang Agro
KO:007590
|
Korea | ₩98.77 Billion |
|
HCL Infosystems Limited
NSE:HCL-INSYS
|
India | ₹7.25 Billion |
|
Llorente & Cuenca S.A.
MC:LLYC
|
Spain | €47.82 Million |
|
Monami
KO:005360
|
Korea | ₩100.64 Billion |
|
Coliseum Acquisition Corp. Class A Ordinary Share
NASDAQ:MITA
|
USA | $5.25 Million |
|
Wanted Lab Inc.
KQ:376980
|
Korea | ₩23.81 Billion |
|
Bitmine Immersion Technologies Inc
PINK:BMNR
|
USA | $4.65 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Avicanna Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Avicanna Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Avicanna Inc (2016–2024)
The table below shows the annual total liabilities of Avicanna Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $10.38 Million | -25.89% |
| 2023-12-31 | $14.00 Million | -1.14% |
| 2022-12-31 | $14.16 Million | -8.01% |
| 2021-12-31 | $15.39 Million | -5.25% |
| 2020-12-31 | $16.25 Million | +6.26% |
| 2019-12-31 | $15.29 Million | +748.74% |
| 2018-12-31 | $1.80 Million | +41.13% |
| 2017-12-31 | $1.28 Million | +939.73% |
| 2016-12-31 | $122.76K | -- |